Denosumab, an adjunctive method in central giant cell granuloma treatment: A case report

Central giant cell granuloma (CGCG) is a benign intraosseous pathology. A 17 years old male patient was referred and diagnosed with CGCG from mandibular right first molar to mandibular left second premolar. Enucleation and curettage of the lesion were completed as the main treatment. Involved teeth on the right, 41, 42, 43, 44, and 45 (FDI) were extracted. As adjunctive therapy, 120 mg Denosumab was injected subcutaneously. The patient received sixteen sessions of therapy through 11 months. Two, sixteen, and eighteen months follow-up after the first session of injection showed an acceptable improvement in bone contour. The patient experienced no functional or aesthetic impairment. Alongside the promising results of Denosumab as adjunctive therapy in the management and treatment of diseases such as CGCG, some questions have remained unanswered and no protocol has been determined. The authors of the current study recommend further researches to confirm Denosumab as a potential adjunctive or alternative in the treatment of CGCG.